Negative symptoms in schizophrenia: new pharmacological approaches

L'Encéphale
M-A LodovighiJ-M Azorin

Abstract

The management of negative symptoms appears to be a major challenge because of functional disability induced by these symptoms and their relative resistance to treatments currently on the market. The aim of this article is to review new approaches that may enable optimal management of these symptoms. First, we describe the methodological difficulties that hindered the development and evaluation of specific treatment, and objectives currently defined to enable the development of new pharmacological approaches. Then we present the monotherapy and adjuvant therapies that have been assessed, including first and second generation antipsychotics, psychostimulants, antidepressants, cholinergic and glutamatergic agents, the oxytocin, hormones and more invasive therapies such as transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT). Other molecules are under development and evaluation such alpha-7 nicotinic receptor agonists.

References

Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Jan 1, 1985·Schizophrenia Bulletin·W T CarpenterL D Alphs
Dec 1, 1986·Journal of Clinical Psychopharmacology·H Y MeltzerD J Luchins
May 1, 1988·The American Journal of Psychiatry·W T CarpenterA M Wagman
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jul 1, 1993·Journal of Psychiatric Research·B N AxelrodL D Alphs
Jan 1, 1994·The American Journal of Psychiatry·A BreierW T Carpenter
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B GallhoferH Gruppe
May 1, 1997·International Clinical Psychopharmacology·W Rein, S Turjanski
Mar 26, 1998·Biological Psychiatry·C ModahlH Levin
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·J C SpellerJ L Alberts
Apr 16, 2003·Schizophrenia Bulletin·Jitschak G StorosumAndré W Broekmans
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Nov 14, 2006·Schizophrenia Bulletin·Robert W Buchanan
Aug 31, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Amir KrivoyTsvi Fischel
Nov 16, 2007·Journal of Clinical Psychopharmacology·Donald C GoffElizabeth L Webster
Apr 3, 2008·The American Journal of Psychiatry·Robert FreedmanWilliam R Kem
Jul 3, 2008·The American Journal of Psychiatry·Anantha ShekharChristian C Felder
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·John R GeddesGuy M Goodwin
Mar 19, 2009·JAMA : the Journal of the American Medical Association·Nora D VolkowKaren Apelskog-Torres
Jun 29, 2010·Trends in Pharmacological Sciences·Caline S KaramJonathan A Javitch
Jul 10, 2010·Biological Psychiatry·David FeifelAllison Hadley
Sep 3, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Surendra P SinghKelvin Chan
Nov 11, 2010·Schizophrenia Research·Jayashri KulkarniHenry Burger
Jan 29, 2011·Schizophrenia Bulletin·Stephen R MarderRichard S E Keefe
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carrie K JonesMichael Bubser
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bita Moghaddam, Daniel Javitt
Mar 24, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Michael J PelusoPeter B Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Michael C DavisStephen R Marder
Technology Evaluation Center Assessment Program. Executive Summary
© 2022 Meta ULC. All rights reserved